7 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityBody Weight, Nutritional and Metabolic Diseases, Obesity, Abdominal, Overweight, Pathological Conditions, Signs and Symptoms, Prehypertension, Signs and Symptoms, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, prediabetes syndrome, vascular disorderRecruitingPhase 32026-10-08NCT07794579
A Study of Brenipatide in Participants With Alcohol Use DisorderAlcohol Use Disorder, Chemically-Induced Disorders, alcohol-related disorders, psychiatric disorder, substance-related disorderRecruitingPhase 32026-10-08NCT07219953
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urinary Incontinence, Urinary Incontinence, Stress, Urination Disorders, Urogenital Diseases, Urological Manifestations, urinary system disorderRecruitingPhase 32026-10-08NCT07202884
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver diseaseRecruitingPhase 32026-10-08NCT07165028
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use DisorderAlcohol Use Disorder, Chemically-Induced Disorders, alcohol-related disorders, psychiatric disorder, substance-related disorderRecruitingPhase 32026-10-07NCT07219966
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisDigestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitisActive, not recruitingPhase 22026-09-11NCT06029972
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataPathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, alopecia, disorder of pilosebaceous unit, hypotrichosis, skin disorderRecruitingPhase 32026-09-08NCT05723198